Skip to Content

The Impact of Adding Nivolumab to First-Line Chemotherapy in Patients with Advanced Gastric Cancer

Nivolumab plus chemotherapy (Nivo-Chemo) is the standard treatment for advanced gastric cancer. However, real-world data on the efficacy of Nivo-Chemo are limited. In this MEDtalk, Dr. Mai Utsumi presents a study on the impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer.

Mai Utsumi

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top